<DOC>
	<DOCNO>NCT00157248</DOCNO>
	<brief_summary>To determine long term safety efficacy BIBR 1048 patient chronic atrial fibrilla tion , without concomitant chronic treatment acetylsalicylic acid ( ASA ) .</brief_summary>
	<brief_title>Long-term , Open-label Follow-up Treatment Patients With A-fib Who Have Been Previously Treated With BIBR 1048</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<criteria>Inclusion criterion Diagnosis main criterion inclusion : Paroxysmal , persistent , permanent ( chronic ) nonrheumatic atrial fibrillation history coronary artery disease ( CAD ) previous treatment BIBR 1048 PETRO ( trial 1160.20 NCT01227629 ) premature discontinuation therapy paroxysmal , persistent , permanent ( chronic ) nonrheumatic atrial fibrillation , document electrocardiogram ( ECG ) least twice prior enrollment PETRO concomitant coronary artery disease additional risk factor stroke ( one follow conditions/events ) : hypertension , diabetes mellitus ( DM ) , congestive heart failure ( CHF ) Left ventricular dysfunction ( LVD ) , previous ischemic stroke transient ischemic attack ) TIA , age great 75 year . age &gt; = 18 year write , informed consent Exclusion criterion Valvular heart disease confer significantly increase risk thromboembolic event ( e.g . clinically significant mitral stenosis prosthetic valve ) . plan cardioversion patient study . contraindication anticoagulant therapy ( previous intracranial hemorrhage , gastrointestinal ( GI ) hemorrhage within previous 3 month , previous severe hemorrhage warfarin therapeutic international normalize ratio ( INR ) , regular use nonsteroidal antiinflammatory drug , hemorrhagic diathesis ) major bleed within last 6 month ( GI hemorrhage ) . severe renal impairment ( estimate glomerular filtration rate [ GFR ] &lt; = 30 mL/min ) . uncontrolled hypertension ( systolic blood pressure [ SBP ] &gt; 180 mm Hg and/or diastolic blood pressure [ DBP ] &gt; 100 mmHg ) . Women pregnant childbearing potential refuse use medically acceptable form contraception throughout study ( note : negative pregnancy test must obtain woman childbearing potential prior entry study ) . Patients receive investigational drug BIBR 1048 within last 30 day . Patients consider unreliable investigator concern requirement followup study and/or compliance study drug administration . Another indication anticoagulant treatment ( eg , deep vein thrombosis pulmonary embolus ) . Clinically significant anemia ( note : patient mildmoderate anemia enrol possibility GI bleed source evaluate , etiology anemia identify , appropriate action take ) . Patients suffer thrombocytopenia ( platelet &lt; 100,000/uL ) . Any condition , discretion investigator , would allow safe participation study . Continuing planned concomitant treatment antiplatelet agent acetylsalicylic acid ( ASA ) . Recent malignancy radiation therapy ( &lt; = 6 month ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>